Tuesday, 9 June 2020

Cold Pain Therapy Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Scenario:
Cold pain therapy includes the products used to reduce the pain or inflammation caused by some physical activities such as injury cause during playing or sports activity and sprain in muscle or ligament during gym. Cold therapy includes use of ice or gel packs that are kept in the freezer till needed. This therapy is largely preferred to manage the pain and swelling as it is simple to use, less expensive and gives quick results.
The market of cold pain therapy is expected to grow by increasing the demand for products to reduce the pain without medicines or by reducing the use of medicine consumption. Cold pain therapy is also use for the treatment of tennis elbow, iliotibial band syndrome, plantar fasciitis, carpel tunnel syndrome and patellofemoral pain syndrome and many more. The cold pain therapy treatment market growth was estimated USD 1.62 billion in 2017 and expected to reach USD 2.12 billion by 2023 at a CAGR of 4.6% during the forecast period. Most of the cold pain therapy are over the counter products available on online pharmacies, retailing or medical shops.  
Segmentation:
The global cold pain therapy market is segmented on the basis of product, application, therapy, and end-user. The cold pain therapy market, by product is segmented into over the counter (OTC) and prescription products. The over the counter products are sub segmented into gels, sprays, patches, cold packs, wraps, pads, and roll-ons use for the treatment of injuries.
The prescription products are sub segmented into motorized and non-motorized devices.
On the basis of application, the cold pain therapy market is segmented into musculoskeletal disorders, post-operative therapy, sports medicine, and post-trauma therapy.
On the basis of therapy, the cold pain therapy market is segmented into icepack therapy, chamber therapy and cryosurgery.
On the basis of end-user, the cold pain therapy market is segmented into hospitals and clinics, sports person, adults, and others.
Key Players:
Some of the key players in the global cold pain therapy market Medline Industries (US), Sanofi (France), Breg (US), DJO Global (US), Pfizer (US), Johnson & Johnson (US), Össur (Iceland), Performance Health (US), Beiersdorf (Germany), Hisamitsu Pharmaceutical (Japan), Rohto Pharmaceutical (US), Romsons Group of Industries (India), and Others.
Regional Analysis:
The Americas is expected to lead the market owing to increase research and development in cold pain therapy, rising demand for the products to reduce the swelling and arthritis pain. According to the Arthritis Foundation it is estimated that 78 million people may be diagnosed with arthritis in 2040. It was also estimated that currently 31 million of Americans are affected with osteoarthritis. The increasing number prevalence of arthritis with in the population may influence the cold pain therapy market.
Europe is anticipated to be the second largest cold pain therapy market during the forecast period. The increasing prevalence of non-traumatic joint disorders such as knee pain, chronic infectious arthritis and crystalline synovitis is rising the demand for cold pain therapy products. The increase in number of surgeries also support the cold pain therapy market.  According to the National Center for Biotechnology Information 2016, publication it was reported that people affected from septic arthritis (SA) ranges between 2 and 10 per 100,000 patients in the US and Western Europe. The increasing geriatric population and increasing cases of arthritis supports the market growth of cold pain therapy market.
Asia-Pacific was expected to be the fastest growing region for the global cold pain therapy market in 2017. The market is expected to witness high growth owing to the increasing geriatric population with arthritis problem and increasing injuries during sports activities, and presence of major players in cold pain therapy market. According to the MoHFW, Government of India, 2017, reported that osteoarthritis is the most common rheumatologic disease affecting the Indian population with the prevalence of 22% to 39%. The increasing prevalence of rheumatologic disease affecting the large number of populations support the cold pain therapy market.
The Middle East and Africa holds the lowest share for cold pain therapy market due to the low per capita income and availability of alternative treatment method. However, the rising demand for pain relieving products may increase the market growth in Middle East and Africa.
Posted by at No comments:

Global Transthyretin (TTR) Amyloidosis Market Set For Big Growth - Foresight By 2023

Market Scenario
The Transthyretin (TTR) amyloidosis market size is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Transthyretin Amyloidosis (ATTR) Market share and trends analysis on Regional basis, Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy global Transthyretin (TTR) amyloidosis market share. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.
Posted by at No comments:

Medical Gases and Equipment Market 2023 – Market Size, Share, Trends Analysis And Growth Forecast

Market Highlights:
The Global Medical Gases and Equipment Market held a market value of USD 13.0 billion in 2017 and is projected to grow at a CAGR of 7.5% over the forecast period. Medical gas is defined as the gas is manufactured, packaged, and used for administration to patients in diagnosis, anesthesia, and therapy. Medical gases are the life-saving element that provides direct influence in maintaining the life of patients. Medical gas equipment are the supply systems used by hospitals & clinics, academic & research institutions, pharmaceutical & biotechnology industries to create or distribute medical gases in the piping system. Few of the market growth factors are globally growing geriatric population coupled with increasing prevalence of chronic diseases, the presence of favorable government initiatives such as industry-friendly safety, and rising demand for point of care products & home healthcare. The Centers for Disease Control and Prevention (CDC) reported that, in the US, 6 in 10 adults have a chronic disease and 4 in 10 adults have two or more chronic diseases such as heart disease, cancer, chronic lung disease, stroke, diabetes, and chronic kidney disease (CKD)
Regional Analysis:
The Global Medical Gases and Equipment Market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On the basis of region, the Americas is likely to dominate the global medical gases and equipment market owing to the increasing adoption of advanced technologies and the presence of major market players & target population in the U.S. and Canada. Europe will hold the second largest market position over the forecast period due to flourishing growth in medical device industry and the presence of medical gas associations, viz. the MGA (Medical Gas Association) and EIGA (European Industrial Gases Association)
The Asia-Pacific is anticipated to witness comparatively higher CAGR during the forecast period owing to growing population in India and China, increasing awareness among patients, caregivers and healthcare professionals about medical gases, and developing healthcare infrastructure in the region. The Middle East & Africa has the least share of the global medical gases and equipment market. Additionally, the major market share of the region would be held by the Middle East region attributed to rising incidences of conventional diseases and increasing technological innovations in the UAE, Saudi Arabia and Qatar.
Segmentation:
The global medical gases and equipment market has been segmented into product, application, and end user.By product, the market has been segmented into medical gases, medical gas mixtures, and medical gas equipment. The medical gases segment has been further categorized into nitrogen gas, nitrous oxide gas, oxygen gas, carbon dioxide gas, helium gas, and medical air.
The medical gas mixtures segment is further categorized into medical laser gas mixtures, medical drug gas mixtures, sterilant gas mixtures, lung diffusion mixtures, blood gas mixtures, aerobic gas mixtures, anaerobic gas mixtures, and breathing zone monitoring calibration standard. The medical gas equipment is further categorized into air compressors, vacuum systems, flow meters, cylinders, alarm systems, masks, and others (manifolds, regulators, and outlets).
On the basis of application, the market has been segmented into therapeutic applications, diagnostic applications, pharmaceutical manufacturing & research, and others. The therapeutic applications segment is further categorized into respiratory therapies, cardiovascular therapies, anesthesia delivery, and others.Based on end user, the market has been segmented into hospitals & clinics, academic & research institutions, pharmaceutical & biotechnology companies, and home healthcare.
Key Players:
Some of the prominent players in the global medical gases and equipment market are Atlas Copco, Praxair Technology, Inc., Air Liquide, Airgas, Inc., Amico Corporation, Messer Group GmbH, AB Matheson Tri-Gas, Inc., The Linde Group, TAIYO NIPPON SANSO CORPORATION, SCI Analytical, SOL S.p.A., Rotarex SA, GCE Holding AB, Air Products and Chemicals, Inc., and Matheson Tri-Gas, Inc.
Posted by at No comments:

Worldwide Cerebral Palsy Market Top 10 Players Universal Analysis, Industry Demand And 2023 Forecast

Market Scenario
Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral palsy can develop from several factors such as lack of oxygen to the brain, genetic conditions, brain infections, brain hemorrhage, chemical or substance abuse during pregnancy, injury to the head, and severe jaundice.
The global cerebral palsy treatment market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Regional Summary
The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least cerebral palsy market share over global market owing to the lack of economic development, especially in the African region.
Key players
Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
Posted by at No comments:

Worldwide Neurostimulation Devices Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2022

Market Scenario:
Neurostimulation is a modulation of the nervous system’s activity. It is deliberately carried out by using invasive and non-invasive techniques. Implantable stimulation devices are most commonly used in the treatment of the neurological conditions such as epilepsy, Parkinson’s disease, dystonia, tremors, depression, obsessive compulsive disorder, diabetic neuropathy and few other conditions. Increasing cases of the neurological disorders such as chronic pain and depression high adoption of the Neurostimulation therapy are likely to improve the market of Neurostimulation devices. Globally, this Neurostimulation Devices Market Size is growing steadily and it is anticipated to show an exponential growth reaching approximately $11.5 billion in 2022
Segments:
Global Neurostimulation devices market has been segmented on the basis of type which comprises implantable devices, and external devices. Implantable devices include deep brain stimulators, spinal cord stimulators, sacral nerve stimulators, gastric electric stimulators, cochlear implants, and vagus nerve stimulators; whereas external devices include transcutaneous electrical nerve stimulator, and transcranial magnetic stimulator. On the basis of application, the market is segmented into dystonia, epilepsy, Parkinson's disease, depression, gastroparesis, pain management, tremors, urinary and fecal incontinence, and others. On the basis of end user, market is segmented into hospitals/clinics, cognitive care centers, research institutes and others.
Regional Analysis of Neurostimulation devices Market:
Considering the global scenario of the market, Americas region is believed to be the largest market for Neurostimulation devices. Moreover, the European market is also growing continuously and slowly catching up with the American market. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the Neurostimulation devices segment during the forecast period. Middle East & Africa region are likely to have a limited but steady growth in the market.
Key Players for Neurostimulation devices Market:                                     
Some of the key players in this market are: Autonomic Technologies, Boston Scientific, ElectroCore, ImThera Medical, Inspire Medical Systems, LivaNova (Cyberonics), Medtronic, NeuroMetrix, NeuroPace, Neuros Medical, NeuroSigma, Nevro Corporation, SPR Therapeutics, St.Jude Medical, Synapse Biomedical, and others.   
Regional Market Summary 
Geographically, the Americas is anticipated to dominate the global Neurostimulation Devices market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.
According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the Neurostimulation Devices market in this region.
Europe is expected to hold the second largest market share in the global Neurostimulation Devices market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the Neurostimulation Devices market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the Neurostimulation Devices market during the forecast period.
Posted by at No comments:

The Sepsis Diagnostics Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2022

Sepsis Diagnostics Market– Overview
The development of diagnostic tools for a diverse range of ailments has facilitated the development of the sepsis diagnostic market as well. Market reports connected with healthcare industry have been offered by Market Research Future which creates reports on other industry verticals that intends to analyze the current market scenarios better. The market is on track to attain an 8 % CAGR while earning USD 710 million in the forecast period.
The severity of the symptoms of sepsis necessitate the availability of accurate tests that can detect the ailment at the initial stages. The sepsis diagnostic market is expected to be motivated by the escalating level of investments from industry players. The enhanced collection of patient outcome information and incorporation into medical records is anticipated to additionally inspire the expansion of thesepsis therapeutics market in the forecast period.
Segmental Analysis
The segmental analysis of the sepsis diagnostics market has been carried out on the basis of technology, product type, end-user, and region. Based on technology, the sepsis diagnostic market consists of biomarkers, molecular diagnostics, immunoassays, and others. By type of products, the sepsis market is segmented into instruments, kits, blood culture media, and others. Based on end users, the sepsis diagnostic market is segmented into specialty clinics, hospitals, pathology laboratories, diagnostic centers, and others. The regions that are considered in the sepsis diagnostic market are the Americas, Europe, Asia Pacific, Middle East, and Africa.
Detailed Regional Analysis
The region-based study of the sepsis diagnostic market includes regions such as Americas, Europe, Asia Pacific, Middle East, and Africa. The North American region is the major market for medical tourism which is expected to motivate the development of the sepsis market in the forecast period. The North American market for sepsis diagnostics is anticipated to achieve USD 320 million by the end of the forecasted period. The European region is the next prime market for sepsis diagnostics which is anticipated to develop at the CAGR of 6.8%. While the Asia Pacific region is anticipated to be the most rapidly growing region in sepsis diagnostics market.
Competitive Analysis
The current implementation of strategies is expected to motivate the market in the impending years. The development of a strong value chain is moreover motivating the expansion of the market. The vertical additions and product tactics of the market are enhancing the potential of the market companies. Substantial cutbacks in administrative budgets are bringing further development of the market. The augmented conformity of market players to new clients and market trend predispositions are advancing the growth curve of the market and will continue in the forecast period. The calculated goals envisioned for the market are buoyed due to useful product differentiation supported by market contestants. The expansion of the market is moving in a favorable direction due to original product introductions or escalating gross revenue of the players in the market.
The prominent competitors in the sepsis diagnostic market are EKF Diagnostics (UK), T2 Biosystems, Inc. (US), bioMérieux, Inc. (US), Becton, Dickinson and Company (US), Sandstone Diagnostics, Inc. (US), Immunexpress (US), Axis-Shield Diagnostics Ltd. (Scotland), Cube Dx GmbH (Austria), and others.
Industry Updates:
Dec 2018 Beckman Coulter, which is an international leader in the clinical diagnostics industry has announced that it is joining forces with Sepsis Alliance, the nation's leading sepsis organization, to support the Sepsis Coordinator Network. The pioneering online, peer-to-peer alliance for healthcare professionals, the Sepsis Coordinator Network is dedicated to saving lives by advancing patient results.
May 2018 Mobidiag, a Finnish firm, has obtained funding to creäte a rapid molecular sepsis assay on its Novodiag system. The fresh funding comprises of a €1.5 million ($1.74 million) loan for the first year of the project provided by Business Finland, a funding agency previously known as Tekes.
Posted by at No comments:

Regenerative Medicine Market Staggering Double Digit Cagr Till 2022

Global Regenerative Medicine Market - Overview
The global market for regenerative medicine is growing steadily. Factors that influence the regenerative medicine market are increasing advancement in healthcare technology, increasing prevalence of chronic diseases and the rising growth in stem cell technology is driving the growth of the market.
The demand for biologically derived materials for regenerative medicine is currently high due to its efficiency over other naturally derived materials. During the surgical procedures, synthetic materials are more preferred as they provide better outcome. Increase in demand for material reengineering and cell biology with the recent progress in the design of synthetic materials have led to the use of hydrogel in the formation of tissue-engineered scaffolds.
Furthermore, the increasing incidence of degenerative diseases and shortage of organs for transplantation are expected to boost the growth of the market. The prominent potential of regenerative medicine to replace, repair, and regenerate damaged tissues and organs has boosted the market growth. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has spurred the growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth
Numerous government bodies are encouraging the growing regenerative medicine market. For instance, National Institutes of Health (NIH) supports scientific research community through NIH Regenerative Medicine Program, International SC Research, State Initiatives for Stem Cell Research, NIH SC Unit, NIH SC Libraries & Projects, and NIH SC Translation Laboratory. However, identifying the potential clinical applications in countries such as U.S., UK, China, and Japan have introduced changes in their regulatory policies to encourage research. Thus, the industry is projected to reflect accelerated growth over the forecast period.
Globally the regenerative medicine market is expected to grow at the rate of about 25.4% from 2016 to 2022.
Industry Updates
October, 2017 Advanced Medical Solutions Group and Organogenesis Inc. enter into patent out-licensing agreement. The companies have agreed on the US patent on the collagen-based wound dressing containing Polyhexamethylene Biguanide
July, 2017 Baxter International Inc., a global medical products company announced the acquisition of Claris Injectables Limited. The acquisition is expected to broaden Baxter’s presence in the generic pharmaceuticals market and will boost the supply of essential medicines to the customers.
March, 2017 Organogenesis Inc. has acquired NuTech Medical. The newly-formed company has expanded product portfolio for the wound care and surgical biologics markets.
Global Regenerative Medicine Market - Regional Analysis
Global Regenerative medicine market, on the basis of regions is divided into Americas, Europe, Asia Pacific and Middle East and Africa.
North America is estimated with highest share in revenue owing to presence of major players and rapid advances in technology along with high investments in stem cell & oncology research. Furthermore, active presences of organizations such as Alliance for Regenerative Medicine, National Institutes of Health, National Cancer Institute, International Society for Stem Cell Research, and National Stem Cell Foundation that promote R&D of regenerative medicine is expected to further accelerate growth in this region.
Europe is the second-largest market for regenerative medicine. Asia Pacific is projected to witness fastest growth over forecast period owing to high investments in healthcare research by the emerging economies in the region. Advances in stem cell research and presence of flexible regulatory environment for clinical adoption of cell-based regenerative therapies, China and Japan are expected to reflect rapid industrial progress.
Global Regenerative Medicine Market - Company Analysis
The global regenerative medicine market is observed to be highly competitive and fragmented. The key entities are perceived to have high investments in development of regenerative therapies to capture the untapped potential by innovating novel therapies to meet the demand for unmet clinical needs.
In addition, key players are witnessed to focus on oncology & age-related degenerative disorders to compete in the market. Thereby, the industry witnesses a strong pipeline of products in clinical trials, which eventually are expected to drive revenue generation.
Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), NuVasive, Inc. (U.S.), Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), C.R. Bard (U.S.), RTI surgical (U.S.), Baxter International, Inc. (U.S.), Advanced Cell Technology (U.S.), CryoLife (U.S.), Sanofi (France), BioMimetic Therapeutics (U.S.), StemCells Inc. (U.S.), LifeCell Kinetic Concepts (U.S.) and others are some of the prominent players at the forefront of competition in the global regenerative medicine market and are profiled in MRFR Analysis. 
Posted by at No comments:
Subscribe to: Posts (Atom)